Teva-Sanofi's 2025 Ulcerative Colitis & Crohn’s Drug Shows Promising Phase 2b Results, Stock Surges
Teva Pharmaceuticals and Sanofi reveal encouraging Phase 2b trial outcomes for their innovative treatment targeting ulcerative colitis and Crohn’s disease, setting the stage for Phase 3 studies in 2025.
Bill McColl brings over 25 years of expertise as a senior producer and writer across TV, radio, and digital platforms, leading teams in delivering impactful news coverage on major global events.
Highlights
- Teva Pharmaceuticals and Sanofi announced positive Phase 2b clinical trial results for their novel drug addressing ulcerative colitis and Crohn’s disease.
- Detailed findings will be presented at a leading scientific conference scheduled for 2025.
- Plans are underway to initiate Phase 3 clinical trials following regulatory consultations.
- Following the announcement, Teva’s U.S.-listed shares soared to a six-year peak, while Sanofi’s shares also experienced significant gains.
On Tuesday, shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) traded on the U.S. stock market surged after unveiling promising Phase 2b trial data for their drug candidate targeting ulcerative colitis (UC) and Crohn’s disease.
According to Teva’s press release, the human monoclonal antibody duvakitug met primary endpoints in the trial, with UC patients receiving low and high doses achieving clinical remission rates of 36.2% and 47.8%, respectively—substantially outperforming placebo groups.
For patients with Crohn’s disease, remission rates were 26.1% at the low dose and 47.8% at the high dose, also significantly exceeding placebo outcomes.
Groundbreaking Study for Crohn’s Disease
Teva highlighted that this trial represents the first randomized, placebo-controlled study evaluating an anti-TL1A monoclonal antibody’s effect on Crohn’s disease. The companies anticipate sharing comprehensive data at a scientific forum in 2025.
Dr. Houman Ashrafian, Sanofi’s Head of Research & Development, emphasized that duvakitug could mark a new frontier in treating inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Teva and Sanofi are preparing to launch Phase 3 clinical trials for duvakitug, contingent upon regulatory discussions.
Following the news, Teva’s shares on U.S. exchanges climbed over 26% to $20.88, reaching their highest price in six years and nearly doubling this year. Sanofi’s shares also rose by more than 7%, closing at $49.10.
For news tips, contact Investopedia reporters at tips@investopedia.com.
Discover engaging topics and analytical content in Markets News as of 15-08-2024. The article titled " Teva-Sanofi's 2025 Ulcerative Colitis & Crohn’s Drug Shows Promising Phase 2b Results, Stock Surges " provides new insights and practical guidance in the Markets News field. Each topic is meticulously analyzed to deliver actionable information to readers.
The topic " Teva-Sanofi's 2025 Ulcerative Colitis & Crohn’s Drug Shows Promising Phase 2b Results, Stock Surges " helps you make smarter decisions within the Markets News category. All topics on our website are unique and offer valuable content for our audience.